Aptose Biosciences
Quarterly Financials
| Values in thousands | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 |
|---|---|---|---|---|
Revenue | $0 | $712 | $712 | $0 |
Gross Profit | -117 | -108 | 599 | -109 |
EBITDA | -7,225 | -9,607 | -12,349 | -11,447 |
EBIT | -7,343 | -9,716 | -12,462 | -11,556 |
Net Income | -7,250 | -9,596 | -12,285 | -11,447 |
Net Change In Cash | 0 | 712 | 712 | 0 |
Free Cash Flow | -5,804 | -11,709 | -9,503 | -10,535 |
Cash | 8,328 | 7,338 | 9,204 | 15,720 |
Basic Shares | 16,754 | 13,133 | 7,942 | 6,495 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -474 | -507 | -616 | -646 |
EBITDA | -52,268 | -42,065 | -64,824 | -55,162 |
EBIT | -52,356 | -42,572 | -65,440 | -55,808 |
Net Income | -51,207 | -41,053 | -65,261 | -54,708 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Cost of Revenue | -2,140 | -78,279 | 37,551 | |
Free Cash Flow | -45,437 | -32,346 | -43,516 | -33,970 |
Cash | 9,204 | 36,970 | 39,114 | 117,393 |
Basic Shares | 6,755 | 6,151 | 5,939 | 5,455 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.37 |
2024-06-30 | -$0.43 |
2024-03-31 | -$0.73 |
2023-12-31 | -$1.44 |
